Effect of Cilostazol Following Endovascular Intervention for Peripheral Artery Disease

Angiology

Volumn 66, Issue 8, 2015, Pages 774-778

  Nanto, Kiyonori ^a   Iida, Osamu ^a   Takahara, Mitsuyoshi ^b   Soga, Yoshimitsu ^c   Suzuki, Kenji ^d   Hirano, Keisuke ^e   Kawasaki, Daizo ^f   Shintani, Yoshiaki ^g   Suematsu, Nobuhiro ^h   Yamaoka, Terutoshi ⁱ   Uematsu, Masaaki ^a  

^a KANSAI ROSAI HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KOKURA MEMORIAL HOSPITAL   (Japan)

^d SENDAI KOUSEI HOSPITAL   (Japan)

^e SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

^f Morinomiya Hospital   (Japan)

^g Shinkoga Hospital   (Japan)

^h FUKUOKA RED CROSS HOSPITAL   (Japan)

ⁱ MATSUYAMA RED CROSS HOSPITAL   (Japan)

Author keywords

cilostazol; peripheral artery disease; restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; THIENOPYRIDINE DERIVATIVE; ALLOY; CARDIOVASCULAR AGENT; NITINOL; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOVASCULAR THERAPY; FEMALE; HEMODIALYSIS; HUMAN; HYPERTENSION; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MAJOR CLINICAL STUDY; MALE; NITINOL STENT; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RESTENOSIS; RETROSPECTIVE STUDY; SMOKING; TREATMENT DURATION; VASCULAR PATENCY; ADVERSE EFFECTS; CLINICAL TRIAL; DEVICES; ENDOVASCULAR SURGERY; FACTUAL DATABASE; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODEL; PROSTHESIS; RECURRENT DISEASE; RISK FACTOR; STENT; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALLOYS; CARDIOVASCULAR AGENTS; DATABASES, FACTUAL; ENDOVASCULAR PROCEDURES; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; STENTS; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 84939486989     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319714551361     Document Type: Article

References (22)

1. Morris-Stiff G, Ogunbiyi S, Rees J, Davies CJ, Hicks E, Lewis MH,. Variations in the anatomical distribution of peripheral vascular disease according to gender. Ann R Coll Surg Engl. 2011; 93 (4): 306-309.
2. Rowe VL, Lee W, Weaver FA, Etzioni D,. Patterns of treatment for peripheral arterial disease in the United States: 1996-2005. J Vasc Surg. 2009; 49 (4): 910-917.
3. Norgren L, Hiatt WR, Dormandy JA, TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007; 45 (suppl S): S5-S67.
4. Schillinger M, Minar E,. Percutaneous treatment of peripheral artery disease: novel techniques. Circulation. 2012; 126 (20): 2433-2440.
5. Jeffrey L, Jonathan L, Nancy M,. Management of patients with peripheral artery disease (Compilation of 2005 and 2011ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127 (13): 1425-1443.
6. Tendera M, Aboyans V, Bartelink ML, ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the task force on the diagnosis and treatment of peripheral artery diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32 (22): 2851-2906.
7. Soga Y, Iida O, Hirano K, Yokoi H, Nanto S, Nobuyoshi M,. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg. 2010; 52 (3): 608-615.
8. Iida O, Yokoi H, Soga Y, STOP-IC investigators. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation. 2013; 127 (23): 2307-2315.
9. Soga Y, Yokoi H, Kawasaki T,. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol. 2009; 53 (1): 48-53.
10. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S,. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg. 2008; 48 (1): 144-149.
11. Capek P, McLean GK, Berkowitz HD,. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation. 1991; 83 (2 suppl): I70-I80.
12. Schillinger M, Sabeti S, Loewe C,. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006; 354 (18): 1879-1888.
13. Laird JR, Katzen BT, Scheinert D, RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010; 3 (3): 267-276.
14. Dake MD, Ansel GM, Jaff MR, Zilver PTX Investigators. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013; 61 (24): 2417-2427.
15. Regensteiner JG, Stewart KJ,. Established and evolving medical therapies for claudication in patients with peripheral arterial disease. Nat Clin Pract Cardiovasc Med. 2006; 3 (11): 604-610.
16. Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, Polson JB,. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol. 1994; 48 (4): 827-835.
17. Jang JS, Jin HY, Seo JS,. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology. 2012; 122 (3): 133-143.
18. Douglas JS, Holmes DR, Kereiakes DJ, Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005; 112 (18): 2826-2832.
19. Tsuchikane E, Fukuhara A, Kobayashi T,. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999; 100 (1): 21-26.
20. Suh JW, Lee SP, Park KW,. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol. 2011; 57 (3): 280-289.
21. Warner CJ, Greaves SW, Larson RJ,. Cilostazol is associated with improved outcomes after peripheral endovascular interventions. J Vasc Surg. 2014; 59 (6): 1607-1614.
22. Hagenaars T, Gussenhoven EJ, van Sambeek MR, Jukema JW, Kranendonk SE, Bom N,. Effect of simvastatin on restenosis after percutaneous transluminal angioplasty of femoropopliteal arterial obstruction. Am J Cardiol. 2000; 86 (7): 774-776.